Linsitinib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Ewing Sarcoma
Conditions
Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma
Trial Timeline
Mar 1, 2014 → Jul 15, 2016
NCT ID
NCT02546544About Linsitinib
Linsitinib is a phase 2 stage product being developed by Astellas Pharma for Relapsed Ewing Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02546544. Target conditions include Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Ewing Sarcoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02546544 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsed Ewing Sarcoma